Why Gland Pharma’s Enoxaparin Sodium Injection is built for quiet reliability in critical care

Reviewed: ad hoc news Software & Services desk. Edited and checked on 2026-06-19, 00:56. Details in the imprint.

With Gland Pharma’s Enoxaparin Sodium Injection, there is no glossy retail box - just a clear prefilled syringe that quietly decides whether a clot forms or not. Nurses snap off the needle cap, check the dose, and deliver a low molecular weight heparin that is built for routine under pressure.

What Enoxaparin is used for

Enoxaparin Sodium Injection is a low molecular weight heparin used to prevent and treat venous thromboembolism, including deep vein thrombosis and pulmonary embolism, especially around surgery or during prolonged immobilization.

Gland Pharma highlights it among its anticoagulant injectable portfolio, which also spans heparin and other critical-care molecules for global markets.

How Gland Pharma formulates it

The Enoxaparin product is supplied as a sterile injectable solution in prefilled syringes, designed for subcutaneous administration with strengths tailored to body weight-based dosing.

Gland Pharma emphasizes its vertically integrated model, controlling key steps from active ingredient sourcing to finished injectables in US FDA and EMA-approved facilities, which is crucial for sensitive anticoagulant products.

Everyday handling on the ward

On the ward, nurses pull Enoxaparin Sodium Injection from a blister tray, feel the familiar resistance of the plunger, and check the embossed dose before administration. The clear barrel and printed scale help avoid confusion in hectic shifts.

Once injected into the abdomen or thigh, the small-gauge needle and pre-set volume keep the injection quick and relatively comfortable, which matters when patients receive daily or twice-daily prophylaxis for days.

Position in Gland’s portfolio

Enoxaparin sits alongside heparin, anticoagulant mixtures, and other hospital generics in Gland Pharma’s sterile injectables portfolio aimed at regulated markets like the US, Europe, and India.

Third-party and contract manufacturing partners often rely on Gland to supply such ready-to-market formulations, allowing branded marketing partners to focus on front-end distribution.

Regulatory and quality backdrop

As a complex injectable anticoagulant, enoxaparin requires strict control of molecular weight distribution and anti-Xa activity, with batch testing aligned to pharmacopeial standards in the US and Europe.

Gland’s facilities that handle Enoxaparin Sodium Injection are inspected by major regulators, including the US FDA, supporting exports under partner labels into highly regulated markets.

Availability and market focus

Gland Pharma primarily sells its Enoxaparin Sodium Injection through B2B and contract development and manufacturing channels, meaning end-users usually see their local hospital brand name rather than Gland’s own.

The product is directed at hospitals and institutional buyers in India and overseas, and is not a consumer-facing pharmacy brand in Germany or other European retail channels.

Where it fits for investors

Gland Pharma Ltd, listed in India, treats Enoxaparin Sodium Injection as part of its broader anticoagulant and critical-care injectable franchise, which contributes to its export-led revenue mix.

Shares of Gland Pharma Ltd (INE025W01027) trade on the NSE and BSE in India, where investors track demand for key injectables like Enoxaparin as part of the company’s growth story.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.